Table 1.
Cell surface markers defining neutrophil developmental states
| Acronym | Full name | Function | Surface markers (mouse) | Surface markers (human) | Overlapping states | References |
|---|---|---|---|---|---|---|
| CMP | Common myeloid progenitors | High proliferation, low self-renewal, multipotent | LKS− CD34int CD16/32int Flt3+ CD115lo
Antibody combination excludes monocyte-DC progenitors, known as “MDP” |
Lin− CD34+ CD38+ CD45RA− | Kwok et al., 2020; Yanez et al., 2017 | |
| GMP | Granulocyte–monocyte progenitors | High proliferation, low self-renewal, oligopotent | LKS− CD34+ CD16/32hi Ly6C−
Antibody combination excludes committed granulocyte progenitors and monocyte progenitors |
Lin− CD34+ CD38+ CD45RA+ | Yanez et al., 2017; Kwok et al., 2020 | |
| proNeu1 | Pro-neutrophils (stage 1) | Committed progenitors; expand in BM during emergency granulopoiesis at the expense of monocytes | LKS− CD34+ CD16/32hi Ly6C+ CD115lo CD81+ CD11b− CD106− | CD15+ CD66b+ CD11b+ CD49dhi SSClo (also CD34lo CD38lo) | Mouse: G0 (Xie et al., 2020); Human: eNeP/N1 (Dinh et al., 2020) |
Kwok et al., 2020; Evrard et al., 2018 |
| proNeu2 | Pro-neutrophils (stage 2) | Intermediate progeny; do not expand during emergency granulopoiesis | LKS− CD34+ CD16/32hi Ly6C+ CD115lo CD81+ CD11b+ CD106+ | CD15+ CD66b+ CD11b+ CD49dint SSChi (also CD34− CD38−) | Mouse: G1 (Xie et al., 2020); Human: N1 (Dinh et al., 2020) |
Kwok et al., 2020; Evrard et al., 2018 |
| preNeu | Neutrophil precursors | High proliferation, low motility, low effector functions; expand in BM and spleen during emergency granulopoiesis | LCS− cKitint Ly6C+ CD11b+ Ly6Glo CXCR2− CXCR4hi | CD15+ CD66b+ CD11b+ CD49dint CD101− | Mouse: G2 (Xie et al., 2020), NeuP (Kim et al., 2017), C1/NeP (Zhu et al., 2018); Human: N2 (Dinh et al., 2020) |
Kwok et al., 2020; Evrard et al., 2018 |
| immNeua | Immature neutrophils | Intermediate proliferation, motility and effector functions | LCS− cKitlo Ly6Clo CD11b+ Ly6Gint CXCR2− CXCR4lo | CD15+ CD66b+ CD11b+ CD49d− CD101+ CD16int CD10− | Mouse: G3 (Xie et al., 2020), C2 (Zhu et al., 2018); Human: N3 (Dinh et al., 2020) |
Kwok et al., 2020; Evrard et al., 2018 |
| mNeua | Mature neutrophils | Low proliferation, high motility, high effector functions | LCS− cKit− Ly6Clo CD11b+ Ly6Ghi CXCR2+ CXCR4− | CD15+ CD66b+ CD11b+ CD49d− CD101+ CD16hi CD10+ | Mouse: G4 (BM) and G5 (blood; Xie et al., 2020); Human: N4 and 5 (Dinh et al., 2020) |
Kwok et al., 2020; Evrard et al., 2018 |
LKS+, Lin− cKit+ Sca1+; LKS−, Lin− cKit+ Sca1−; LCS−, Lin− CD115− SiglecF−; Lin, cocktail of lineage marker antibodies, which should include anti-CD11b up to the GMP stage, but exclude it for analysis of proNeu-mNeu.
CXCR2 can be downregulated within tumors; to define mouse immNeu and mNeu in this context, CD101 can be used (CD101− immNeu and CD101+ mNeu; Evrard et al., 2018).